Share on StockTwits

Shares of Mallinckrodt PLC (NYSE:MNK) have received a consensus rating of “Hold” from the thirteen ratings firms that are covering the stock, Analyst Ratings Network reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $70.90.

Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Mallinckrodt PLC from $82.00 to $90.00 in a research note on Thursday, May 22nd. Separately, analysts at Jefferies Group raised their price target on shares of Mallinckrodt PLC from $77.00 to $85.00 in a research note on Monday, May 12th. They now have a “buy” rating on the stock.

Shares of Mallinckrodt PLC (NYSE:MNK) traded up 1.24% on Friday, hitting $78.55. The stock had a trading volume of 280,939 shares. Mallinckrodt PLC has a 52 week low of $41.00 and a 52 week high of $83.03. The stock has a 50-day moving average of $76.2 and a 200-day moving average of $64.9. The company has a market cap of $4.595 billion and a price-to-earnings ratio of 72.04.

Mallinckrodt PLC (NYSE:MNK) last released its earnings data on Thursday, May 8th. The company reported $0.95 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.78 by $0.17. The company had revenue of $557.80 million for the quarter, compared to the consensus estimate of $566.50 million. Mallinckrodt PLC’s revenue was down 4.7% compared to the same quarter last year. On average, analysts predict that Mallinckrodt PLC will post $3.50 earnings per share for the current fiscal year.

In other Mallinckrodt PLC news, Director Melvin D. Booth purchased 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average cost of $76.05 per share, with a total value of $304,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mallinckrodt public limited company (NYSE:MNK) is a global specialty pharmaceuticals company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.